Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998669 · ClinicalTrials.gov registry record · Phase 2
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Juan P. Alderuccio, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT04998669 is a Phase 2 study of Follicular Lymphoma that is actively recruiting participants, run by Juan P. Alderuccio, MD. The registered enrollment target is 100 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04998669, a Phase 2 study of Follicular Lymphoma, is actively recruiting participants, sponsored by Juan P. Alderuccio, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Loncastuximab tesirine
Study Locations (5)
Florida
- Florida Cancer Specialists and Research Institute - Fort Myers
- University of Miami - Miami
Michigan
- University of Michigan - Ann Arbor
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- Allegheny Health Network - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04998669
The ClinicalTrials.gov registry entry for NCT04998669 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The listed sponsor is Juan P. Alderuccio, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT04998669 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04998669 about?
NCT04998669 is a clinical study titled "Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma". The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
What is the current status of trial NCT04998669?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-02-11. Estimated completion is 2030-08-01.
What conditions does trial NCT04998669 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT04998669?
The interventions under investigation include: Rituximab (DRUG), Loncastuximab tesirine (DRUG).
Who is sponsoring clinical trial NCT04998669?
This trial is sponsored by Juan P. Alderuccio, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04998669 being conducted?
This trial has 5 study locations across Florida, Michigan, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.